国际口腔医学杂志 ›› 2022, Vol. 49 ›› Issue (1): 85-93.doi: 10.7518/gjkq.2022022
Bai Huimin(),Zhang Yuwei,Meng Shu,Liu Chengcheng()
摘要:
牙周炎是由牙菌斑生物膜引起的牙周支持组织的慢性炎症性疾病。特异性促炎症消退介质(SPM)是由多不饱和脂肪酸经酶促反应衍生而来的脂质介质,可积极调控炎症的消退,改变微生物组成,缓解疼痛并促进组织再生,有望在牙周炎防治中发挥辅助作用。本文就SPM的分类及作用机制进行综述,并总结了其在牙周组织炎症过程中作用的最新研究进展,以期为牙周炎发生发展机制的研究提供参考,为牙周炎的防治提供新的思路。
[1] | van Dyke TE, Sima C. Understanding resolution of inflammation in periodontal diseases: is chronic inflammatory periodontitis a failure to resolve[J]. Periodontol 2000, 2020,82(1):205-213. |
[2] | Buckley CD, Gilroy DW, Serhan CN, et al. The re-solution of inflammation[J]. Nat Rev Immunol, 2013,13(1):59-66. |
[3] | Serhan CN, Gupta SK, Perretti M, et al. The atlas of inflammation resolution (AIR)[J]. Mol Aspects Med, 2020,74:100894. |
[4] | Decker C, Sadhu S, Fredman G. Pro-resolving ligands orchestrate phagocytosis[J]. Front Immunol, 2021,12:660865. |
[5] | 孟焕新, 张立. 牙周临床治疗Ⅰ.侵袭性牙周炎的诊断及治疗[J]. 中华口腔医学杂志, 2005,40(1):81-84. |
Meng HX, Zhang L. Treatment of periodontol disease:part I.Diagnosis and treatment of aggressive periodontitis[J]. Chin J Stomatol, 2005,40(1):81-84. | |
[6] | Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions[J]. Nat Rev Microbiol, 2018,16(12):745-759. |
[7] | Ali M, Yang F, Jansen JA, et al. Lipoxin suppresses inflammation via the TLR4/MyD88/NF-κB pathway in periodontal ligament cells[J]. Oral Dis, 2020,26(2):429-438. |
[8] | Ye Y, Zhang HW, Mei HX, et al. PDX regulates inflammatory cell infiltration via resident macrophage in LPS-induced lung injury[J]. J Cell Mol Med, 2020,24(18):10604-10614. |
[9] | Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators[J]. J Clin Invest, 2018,128(7):2657-2669. |
[10] | Reinertsen AF, Primdahl KG, Shay AE, et al. Stereoselective synjournal and structural confirmation of the specialized pro-resolving mediator resolvin E4[J]. J Org Chem, 2021,86(4):3535-3545. |
[11] | Dalli J, Chiag N, Serhan CN. Elucidation of novel 13-series resolvins that increase with atorvastatin and c-lear infections[J]. Nat Med, 2015,21(9):1071-1075. |
[12] | Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors[J]. Mol Aspects Med, 2017,58:114-129. |
[13] | Chiang N, Dalli J, Colas RA, et al. Identification of resolvin D2 receptor mediating resolution of infections and organ protection[J]. J Exp Med, 2015,212(8):1203-1217. |
[14] | Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs[J]. Am J Pathol, 2012,180(5):2018-2027. |
[15] | Dalli J, Winkler JW, Colas RA, et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents[J]. Chem Biol, 2013,20(2):188-201. |
[16] | Chiang N, Fredman G, Bäckhed F, et al. Infection regulates pro-resolving mediators that lower antibiotic requirements[J]. Nature, 2012,484(7395):524-528. |
[17] | Arnardottir HH, Dalli J, Norling LV, et al. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation[J]. J Immunol, 2016,197(6):2362-2368. |
[18] | Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation[J]. J Immunol, 2007,178(6):3912-3917. |
[19] | Oh SF, Dona M, Fredman G, et al. Resolvin E2 formation and impact in inflammation resolution[J]. J Immunol, 2012,188(9):4527-4534. |
[20] | Mizraji G, Heyman O, van Dyke TE, et al. Resolvin D2 restrains Th1 immunity and prevents alveolar bone loss in murine periodontitis[J]. Front Immunol, 2018,9:785. |
[21] | Mustafa M, Zarrough A, Bolstad AI, et al. Resolvin D1 protects periodontal ligament[J]. Am J Physiol Cell Physiol, 2013,305(6):C673-C679. |
[22] | Chiang N, de la Rosa X, Libreros S, et al. Novel resolvin D2 receptor axis in infectious inflammation[J]. J Immunol, 2017,198(2):842-851. |
[23] | Chiurchiù V, Leuti A, Dalli J, et al. Proresolving lipid mediators resolvin D1, resolvin D2, maresin 1 are critical in modulating T cell responses[J]. Sci Transl Med, 2016, 8(353): 353ra111. |
[24] | Cheng T, Ding S, Liu SS, et al. Resolvin D1 improves the treg/Th17 imbalance in systemic lupus erythematosus through miR-30e-5p[J]. Front Immunol, 2021,12:668760. |
[25] | Ramon S, Gao F, Serhan CN, et al. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells[J]. J Immunol, 2012,189(2):1036-1042. |
[26] | Maekawa T, Hosur K, Abe T, et al. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway[J]. Nat Commun, 2015,6:8272. |
[27] | 程抒华, 徐华兴, 陈杰, 等. 消退素E1调控牙周膜成纤维细胞改善牙周组织炎症的研究[J]. 口腔生物医学, 2019,10(2):68-72. |
Cheng SH, Xu XH, Chen J, et al. Effects of resolvin E1 on periodontal ligament cells in experimental periodontitis[J]. Oral Biomed, 2019,10(02):68-72. | |
[28] | Serhan CN, Chiang N, Dalli J. The resolution code of a-cute inflammation: novel pro-resolving lipid mediators in resolution[J]. Semin Immunol, 2015,27(3):200-215. |
[29] | Fredman G, Oh SF, Ayilavarapu S, et al. Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1[J]. PLoS One, 2011,6(9):e24422. |
[30] | Hasturk H, Kantarci A, Ohira T, et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis[J]. FASEB J, 2006,20(2):401-403. |
[31] | Lee CT, Teles R, Kantarci A, et al. Resolvin E1 reverses experimental periodontitis and dysbiosis[J]. J Immunol, 2016,197(7):2796-2806. |
[32] | Hasturk H, Kantarci A, Goguet-Surmenian E, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo[J]. J Immunol, 2007,179(10):7021-7029. |
[33] | Alvarez C, Abdalla H, Sulliman S, et al. RvE1 impacts the gingival inflammatory infiltrate by inhibiting the T cell response in experimental periodontitis[J]. Front Immunol, 2021,12:664756. |
[34] | Dalli J, Zhu M, Vlasenko NA, et al. The novel 13S, 14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype[J]. FASEB J, 2013,27(7):2573-2583. |
[35] | Freire MO, van Dyke TE. Natural resolution of inflammation[J]. Periodontol 2000, 2013,63(1):149-164. |
[36] | van Dyke TE. The management of inflammation in periodontal disease[J]. J Periodontol, 2008,79(8 Suppl):1601-1608. |
[37] | Cianci E, Recchiuti A, Trubiani O, et al. Human periodontal stem cells release specialized proresol-ving mediators and carry immunomodulatory and prohealing properties regulated by lipoxins[J]. Stem Cells Transl Med, 2016,5(1):20-32. |
[38] | Pouliot M, Clish CB, Petasis NA, et al. Lipoxin A4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease[J]. Biochemistry, 2000,39(16):4761-4768. |
[39] | Serhan CN, Jain A, Marleau S, et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators[J]. J Immunol, 2003,171(12):6856-6865. |
[40] | Lawrence T, Gilroy DW. Chronic inflammation: a failure of resolution[J]. Int J Exp Pathol, 2007,88(2):85-94. |
[41] | Ali M, Kucko N, Jansen JA, et al. The effect of lipoxin A4 on E. coli LPS-induced osteoclastogenesis[J]. Clin Oral Investig, 2021,25(3):957-969. |
[42] | Mitchell S, Thomas G, Harvey K, et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo[J]. J Am Soc Nephrol, 2002,13(10):2497-2507. |
[43] | Zhao J, Geng WJ, Wan KF, et al. Lipoxin A4 promotes autophagy and inhibits overactivation of macrophage inflammasome activity induced by Pg LPS[J]. J Int Med Res, 2021,49(2):300060520981259. |
[44] | Chen P, Fenet B, Michaud S, et al. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation[J]. FEBS Lett, 2009,583(21):3478-3484. |
[45] | Serhan CN, Fredman G, Yang R, et al. Novel proresolving aspirin-triggered DHA pathway[J]. Chem Biol, 2011,18(8):976-987. |
[46] | Serhan CN, Gotlinger K, Hong S, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes[J]. J Immunol, 2006,176(3):1848-1859. |
[47] | Bang SS, Xie YK, Zhang ZJ, et al. GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain[J]. J Clin Invest, 2018,128(8):3568-3582. |
[48] | Bosviel R, Joumard-Cubizolles L, Chinetti-Gbaguidi G, et al. DHA-derived oxylipins, neuroprostanes and protectins, differentially and dose-dependently modulate the inflammatory response in human macrophages: putative mechanisms through PPAR activation[J]. Free Radic Biol Med, 2017,103:146-154. |
[49] | Tang S, Wan M, Huang W, et al. Maresins: specialized proresolving lipid mediators and their potential role in inflammatory-related diseases[J]. Mediators Inflamm, 2018,2018:2380319. |
[50] | Chiang N, Libreros S, Norris PC, et al. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions[J]. J Clin Invest, 2019,129(12):5294-5311. |
[51] | Marcon R, Bento AF, Dutra RC, et al. Maresin 1, a proresolving lipid mediator derived from Omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis[J]. J Immunol, 2013,191(8):4288-4298. |
[52] | Deng B, Wang CW, Arnardottir HH, et al. Maresin biosynjournal and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages[J]. PLoS One, 2014,9(7):e10-2362. |
[53] | Wang CW, Yu SH, Fretwurst T, et al. Maresin 1 promotes wound healing and socket bone regeneration for alveolar ridge preservation[J]. J Dent Res, 2020,99(8):930-937. |
[54] | Albuquerque-Souza E, Schulte F, Chen T, et al. Maresin-1 and resolvin E1 promote regenerative properties of periodontal ligament stem cells under inflammatory conditions[J]. Front Immunol, 2020,11:585530. |
[55] | Qiu Y, Wu YC, Zhao HM, et al. Maresin 1 mitigates renal ischemia/reperfusion injury in mice via inhibition of the TLR4/MAPK/NF-κB pathways and activation of the Nrf2 pathway[J]. Drug Des Devel Ther, 2019,13:739-745. |
[56] | Dalli J, Ramon S, Norris PC, et al. Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways[J]. FASEB J, 2015,29(5):2120-2136. |
[57] | Dalli J, Vlasakov I, Riley IR, et al. Maresin conjugates in tissue regeneration biosynjournal enzymes in human macrophages[J]. Proc Natl Acad Sci U S A, 2016,113(43):12232-12237. |
[58] | Dalli J, Colas RA, Arnardottir H, et al. Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution[J]. Immunity, 2017,46(1):92-105. |
[59] | Rosenstein ED, Kushner LJ, Kramer N, et al. Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis[J]. Prostaglandins Leukot Essent Fatty Acids, 2003,68(3):213-218. |
[60] | Kesavalu L, Vasudevan B, Raghu B, et al. Omega-3 fatty acid effect on alveolar bone loss in rats[J]. J Dent Res, 2006,85(7):648-652. |
[61] | El-Sharkawy H, Aboelsaad N, Eliwa M, et al. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with Omega-3 Fatty acids and low-dose aspirin[J]. J Periodontol, 2010,81(11):1635-1643. |
[62] | Castro Dos Santos NC, Andere NMRB, Araujo CF, et al. Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: randomized clinical trial[J]. J Periodontol, 2020,91(10):1318-1327. |
[63] | Clish CB, O’Brien JA, Gronert K, et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo[J]. Proc Natl Acad Sci U S A, 1999,96(14):8247-8252. |
[64] | van Dyke TE, Hasturk H, Kantarci A, et al. Proresolving nanomedicines activate bone regeneration in periodontitis[J]. J Dent Res, 2015,94(1):148-156. |
[65] | Wang B, Booij-Vrieling HE, Bronkhorst EM, et al. Antimicrobial and anti-inflammatory thermo-rever-sible hydrogel for periodontal delivery[J]. Acta Biomater, 2020,116:259-267. |
[66] | Ali M, Yang F, Plachokova AS, et al. Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review[J]. Eur J Oral Sci, 2021,129(1):e12759. |
[67] | Osorio Parra MM, Elangovan S, Lee CT. Specia-lized pro-resolving lipid mediators in experimental periodontitis: a systematic review[J]. Oral Dis, 2019,25(5):1265-1276. |
[1] | 傅豫, 何薇, 黄兰. 铁死亡在口腔疾病中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 36-44. |
[2] | 罗晓洁,王德续,陈晓涛. 基于生物信息学分析铁死亡调控基因与牙周炎的关系[J]. 国际口腔医学杂志, 2023, 50(6): 661-668. |
[3] | 黄元鸿,彭显,周学东. 骨碎补在治疗口腔骨相关疾病的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 679-685. |
[4] | 龚美灵,程兴群,吴红崑. 牙周炎与帕金森病相关性的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 587-593. |
[5] | 孙佳,韩烨,侯建霞. 白细胞介素-6-铁调素信号轴调控牙周炎相关性贫血致病机制的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 329-334. |
[6] | 刘体倩,梁星,刘蔚晴,李晓虹,朱睿. 咬合创伤在牙周炎发生发展中的作用及机制的研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 19-24. |
[7] | 李琼,于维先. 白藜芦醇治疗牙周炎及其生物利用度的研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 25-31. |
[8] | 黄伟琨,徐秋艳,周婷. 黄芩苷抑制脂多糖促巨噬细胞氧化应激损伤作用的研究[J]. 国际口腔医学杂志, 2022, 49(5): 521-528. |
[9] | 周剑鹏,谢旭东,赵蕾,王骏. 辅助性T细胞17及白细胞介素17在牙周炎中的作用及机制的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 586-592. |
[10] | 陈荟宇,白明茹,叶玲. 信号素3A与口腔常见病关系的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 593-599. |
[11] | 周佳佳,赵蕾,徐欣. 牙周炎相关基因多态性的研究进展[J]. 国际口腔医学杂志, 2022, 49(4): 432-440. |
[12] | 马玉,左玉,张鑫. 光动力疗法辅助治疗牙周炎治疗效果的Meta分析[J]. 国际口腔医学杂志, 2022, 49(3): 305-316. |
[13] | 钱素婷,丁玲敏,纪雅宁,林军. 微小RNA在牙周炎龈沟液中的表达差异及对牙周炎的调控机制[J]. 国际口腔医学杂志, 2022, 49(3): 349-355. |
[14] | 蒋端,申道南,赵蕾,吴亚菲. 内皮发育调节基因-1与牙周炎相关性的研究进展[J]. 国际口腔医学杂志, 2022, 49(2): 244-248. |
[15] | 安宁,李姣,梅志丹. 骨保护素/核因子-κB受体活化因子/核因子κB-受体活化因子配体信号分子调控牙萌出的研究进展[J]. 国际口腔医学杂志, 2022, 49(1): 116-120. |
|